Clinical Trial Update: A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating KPL-716 for reducing pruritus in chronic pruritic diseases completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pruritus
• Idiopathic Urticaria
• Lichen Planus
• Lichen Simplex Chronicus
• Plaque Psoriasis

Drugs mentioned

• KPL-716

Snippet

Sponsor: Genentech, Inc. | Conditions: Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus | Phase 2 | Status: COMPLETED | Results posted: 2021-12-28